KAZUHIRO IMAI

Dr. KAZUHIRO IMAI

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in Radiology
Verified
Journal Article
Closed access
KIKAZUHIRO IMAI
KAZUHIRO IMAI
YMYoshihiro Minamiya
Yoshihiro Minamiya
KIKouichi Ishiyama
Kouichi Ishiyama
MHManabu Hashimoto
Manabu Hashimoto
HSHajime Saito
Hajime Saito
JOJun-Ichi Ogawa
Jun-Ichi Ogawa
Our findings indicate that arch distance-to-maximum tumor diameter ratios can be a supportive tool used by radiologists and surgeons to determine pleural invasion category and surgical indications for T3 and T4 invasion. PurposeTo develop a simple noninvasive technique for evaluating pleural invasion by using routine preoperative computed tomography (CT).Materials and MethodsThe institutional review board approved this retrospective study, and written informed consent was obtained for performing the initial and follow-up CT studies. Preoperative CT findings (169 patients with possible pleural invasion) and pathologic diagnoses after surgical resection were evaluated. The length of the interface between the primary tumor and neighboring structures (arch distance) and the maximum tumor diameter were measured on CT images, after which arch distance-to-maximum tumor diameter ratios were calculated. Receiver operating characteristic (ROC) curves were used to analyze the ratios.ResultsMedian arch distance-to-maximum tumor diameter ratios for pleural invasion categories (pl1, pl2, pl3) assessed by using the Union Internationale Contre le Cancer TNM staging system were as follows: pl1, 0.206 (25th–75th percentile, 0–0.486); pl2, ...

6 May 2021 in Blood
Verified
Journal Article
Open access
PDF file
WJWei Jia
Wei Jia
JPJonathan C. Poe
Jonathan C. Poe
HSHsuan Su
Hsuan Su
SASarah Anand
Sarah Anand
GMGlenn K. Matsushima
Glenn K. Matsushima
SSStefanie Sarantopoulos
Stefanie Sarantopoulos
Patients with chronic graft-versus-host disease (cGVHD) have increased B cell–activating factor (BAFF) levels, but whether BAFF promotes disease after allogeneic bone marrow transplantation (allo-BMT) remains unknown. In a major histocompatibility complex–mismatched model with cGVHD-like manifestations, we first examined B-lymphopenic μMT allo-BMT recipients and found that increased BAFF levels in cGVHD mice were not merely a reflection of B-cell number. Mice that later developed cGVHD had significantly increased numbers of recipient fibroblastic reticular cells with higher BAFF transcript levels. Increased BAFF production by donor cells also likely contributed to cGVHD, because BAFF transcript in CD4+ T cells from diseased mice and patients was increased. cGVHD manifestations in mice were associated with high BAFF/B-cell ratios and persistence of B-cell receptor (BCR)–activated B cells in peripheral blood and lesional tissue. By employing BAFF transgenic (Tg) mice donor cells, we addressed whether high BAFF contributed to BCR activation in cGVHD. BAFF increased NOTCH2 expression on B cells, augmenting BCR responsiveness to surrogate antigen and NOTCH ligand. BAFF Tg B cells had significantly increased protein levels of the proximal BCR signaling molecule SYK, and high SYK protein was maintained by BAFF after in vitro BCR activation or when alloantigen was present in vivo. Using T cell–depleted (BM only) BAFF Tg donors, we found that BAFF promoted cGVHD manifestations, circulating GL7+ B cells, and alloantibody production. We demonstrate that pathologic production of BAFF promotes an altered B-cell compartment and augments BCR responsiveness. Our findings compel studies of therapeutic targeting of BAFF and BCR pathways in patients with cGVHD.

23 June 2012 in Surgery Today
Verified
Journal Article
Closed access
PDF file
KIKAZUHIRO IMAI
KAZUHIRO IMAI
YMYoshihiro Minamiya
Yoshihiro Minamiya
HSHajime Saito
Hajime Saito
TNTaku Nakagawa
Taku Nakagawa
MIManabu Ito
Manabu Ito
JOJun-Ichi Ogawa
Jun-Ichi Ogawa

1 August 2018 in The American Journal of Surgery
Verified
Journal Article
Closed access
YSYusuke Sato
Yusuke Sato
SMSatoru Motoyama
Satoru Motoyama
AWAkiyuki Wakita
Akiyuki Wakita
YKYuta Kawakita
Yuta Kawakita
JLJiajia Liu
Jiajia Liu
YMYoshihiro Minamiya
Yoshihiro Minamiya

26 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
YSYusuke Sato
Yusuke Sato
SMSatoru Motoyama
Satoru Motoyama
YWYUKI WADA
YUKI WADA
AWAKIYUKI WAKITA
AKIYUKI WAKITA
YKYuta Kawakita
Yuta Kawakita
YMYOSHIHIRO MINAMIYA
YOSHIHIRO MINAMIYA
Background: Neoadjuvant chemoradiotherapy (NACRT) followed by esophagectomy is now the standard treatment for patients with resectable advanced thoracic esophageal squamous cell carcinoma (ESCC) worldwide. However, the efficacy of NACRT followed by esophagectomy with three-field lymph node dissection for clinical Stage III patients and for clinical Stage IVB patients with supraclavicular LN metastasis has not yet been determined. Methods: Between 2008 and 2018, 94 ESCC patients diagnosed as clinical Stage III and 18 patients diagnosed as clinical Stage IVB with supraclavicular LN metastasis as the only distant metastatic factor were treated with NACRT followed by esophagectomy with extended lymph node dissection at Akita University Hospital. Long-term survival and the patterns of recurrence in these 112 patients were analyzed. Results: The median follow-up period of censored cases was 60 months. The five-year OS and DSS rates among the clinical Stage III patients were 57.6% and 66.6%, respectively. The five-year OS and DSS rates among the clinical Stage IVB patients were 41.3% and 51.6%, respectively. The most frequent recurrence pattern was distant metastasis (69.2%) in the Stage III patients and LN metastasis (75.0%) in the Stage IVB patients. Conclusion: NACRT followed by esophagectomy with three-field LN dissection is feasible and offers the potential for long-term survival of clinical Stage III ESCC patients and even clinical Stage IVB patients with supraclavicular LN metastasis as the only distant metastatic factor. At least in patients with upper and middle thoracic ESCC, treating supraclavicular LNs as regional LNs seems to be appropriate.

29 August 2014 in General Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
YIYukako Imai
Yukako Imai
KIKAZUHIRO IMAI
KAZUHIRO IMAI
TKTetsu Kimura
Tetsu Kimura
THTakashi Horiguchi
Takashi Horiguchi
TGToru Goyagi
Toru Goyagi
YMYoshihiro Minamiya
Yoshihiro Minamiya